Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,.

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Abstract Text:

Scott A Tomlins,Bharathi Laxman,Sooryanarayana Varambally,Xuhong Cao,Jindan Yu,Beth E Helgeson,Qi Cao,John R Prensner,Mark A Rubin,Rajal B Shah,Rohit Mehra,Arul M Chinnaiyan,Scott A Tomlins,Bharathi Laxman,Sooryanarayana Varambally,Xuhong Cao,Jindan Yu,Beth E Helgeson,Qi Cao,John R Prensner,Mark A Rubin,Rajal B Shah,Rohit Mehra,Arul M Chinnaiyan,

TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems. Transgenic mice expressing the ERG gene fusion product under androgen-regulation develop mouse prostatic intraepithelial neoplasia (PIN), a precursor lesion of prostate cancer. Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth. These results suggest that TMPRSS2-ERG may not be sufficient for transformation in the absence of secondary molecular lesions. Transcriptional profiling of ERG knockdown in the TMPPRSS2-ERG-positive prostate cancer cell line VCaP revealed decreased expression of genes over-expressed in prostate cancer versus PIN and genes overexpressed in ETS-positive versus -negative prostate cancers in addition to inhibiting invasion. ERG knockdown in VCaP cells also induced a transcriptional program consistent with prostate differentiation. Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention. Our results support previous work suggesting that TMPRSS2-ERG fusions mediate invasion, consistent with the defining histologic distinction between PIN and prostate cancer.

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Publishing Authors By Initials

SA Tomlins,B Laxman,S Varambally,X Cao,J Yu,BE Helgeson,Q Cao,JR Prensner,MA Rubin,RB Shah,R Mehra,AM Chinnaiyan,SA Tomlins,B Laxman,S Varambally,X Cao,J Yu,BE Helgeson,Q Cao,JR Prensner,MA Rubin,RB Shah,R Mehra,AM Chinnaiyan,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Neoplasia (New York, N.Y.)

VOLUME: 10

Page Numbers: 177-88

Journal Abbreviation: Neoplasia

ISSN: 1476-5586

DAY: 19

MONTH: Feb

YEAR: 2008

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100886622

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,.

AFFILIATION: Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.

Country: Canada

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Neoplasia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer, Related Publications

• A Fluorescence In situ Hybridization Screen for E26 Transformation-Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer.
• A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
• A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
• Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
• Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer.
• Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
• Empirical Bayes identification [correction of identication] of tumor progression genes from microarray data.
• Feature selection and molecular classification of cancer using genetic programming.
• Identifying significant associations using free text problem summary lists in a clinical data repository.
• Integrating biomedical knowledge to model pathways of prostate cancer progression.
• Integrative analysis of genomic aberrations associated with prostate cancer progression.
• Integrative biology of prostate cancer progression.
• Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.
• Integrative molecular concept modeling of prostate cancer progression.
• Molecular markers of prostate cancer.
• Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
• Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer,.
• The discovery and application of gene fusions in prostate cancer.
• The role of SPINK1 in ETS rearrangement-negative prostate cancers.